Orphan Drug Approvals — October 28, 2026

The 2026-10-23 supplemental BLA (BLA761262) is a LABELING submission carrying Priority Review and Orphan Drug designations, which signals regulatory prioritization. The specific labeling change and indication are not disclosed, so the commercial magnitude cannot be sized from this data.

Novo Nordisk received a label expansion approval for insulin icodec (AWIQLI FLEXTOUCH) on 2026-10-23. Indication, population, and commercial figures are NOT_DISCLOSED, so impact is limited to confirming the approval event.

Alexion received a label expansion approval for ravulizumab-cwvz (ULTOMIRIS) on 2026-10-21. The indication, patient population, and pricing data are NOT_DISCLOSED, so the approval is recorded as a positive event without a sized commercial effect.

The neutral-signal labeling update requires AbbVie disclosure of what the change covers before its commercial value can be assessed. Clarification would convert the moderate-materiality rating into a sized estimate.

Most approval records in this period lack indication, population, sales, and exclusivity data, which limits the ability to assess commercial durability for the SKYRIZI, AWIQLI FLEXTOUCH, and ULTOMIRIS actions.

Orphan Drug designation (7-year exclusivity) supports premium pricing, but no pricing power data is disclosed for the SKYRIZI or ULTOMIRIS actions, so the pricing outlook remains unquantified.

SKYRIZI (risankizumab-rzaa) supplemental labeling under Priority Review and Orphan Drug designation may broaden AbbVie's commercial footprint once content is disclosed.

AWIQLI FLEXTOUCH (insulin icodec) label expansion adds to Novo Nordisk's diabetes franchise, though scope is undisclosed.

ULTOMIRIS (ravulizumab-cwvz) label expansion strengthens Alexion's rare-disease position, with orphan-scale pricing potential if the population is narrow.

Four approvals across immunology (SKYRIZI), diabetes (AWIQLI FLEXTOUCH), and rare complement-mediated disease (ULTOMIRIS) show broad activity without concentration in one therapeutic area. No therapeutic-area clustering signal is supported by the provided data.

{"entity" => "SKYRIZI (risankizumab-rzaa), AbbVie", "reason" => "Supplemental BLA (BLA761262) approved 2026-10-23 under Priority Review and Orphan Drug designation, with labeling content undisclosed.", "trigger" => "AbbVie disclosure of labeling scope and any commercial or pricing update"}

{"entity" => "AWIQLI FLEXTOUCH (insulin icodec), Novo Nordisk", "reason" => "Label expansion approved 2026-10-23 with no disclosed indication or commercial data.", "trigger" => "Novo Nordisk launch announcement or payer formulary decision"}

{"entity" => "ULTOMIRIS (ravulizumab-cwvz), Alexion", "reason" => "Label expansion approved 2026-10-21 with no disclosed indication, population, or pricing data.", "trigger" => "AstraZeneca or Alexion disclosure of the expanded indication and reimbursement status"}